Elevated liver enzymes are one of the most common “red flags” people see on routine labs—and one of the most misunderstood underwriting issues in life insurance. A single abnormal ALT, AST, or GGT result can trigger delays, postponements, or overly conservative pricing if the file doesn’t clearly explain what’s going on. The good news is that many applicants with elevated liver enzymes still qualify for traditional coverage, including meaningful face amounts, as long as the cause is identified (or reasonably ruled out), functional markers look good, and trends show stability.

At Diversified Insurance Brokers, we specialize in underwriting-heavy cases. With access to 100+ top-rated carriers, we don’t rely on one company’s interpretation of liver labs. Instead, we build a clean, evidence-based submission that answers the underwriter’s real questions upfront—how high the enzymes are, why they’re elevated, and what confirms that the situation is stable or not associated with progressive liver disease.

One of the biggest mistakes we see is applying too quickly with incomplete documentation. If an application reaches underwriting with unexplained abnormal labs, many carriers default to conservative outcomes: postponement, heavy table ratings, or broad “we need more information” requests that drag the process out for weeks. A better approach is a structured submission that clarifies the story before the carrier has to guess.

What “elevated liver enzymes” means in life insurance underwriting

Underwriters don’t treat elevated liver enzymes as a diagnosis by itself. They treat it as a signal that needs context. ALT and AST are commonly associated with inflammation in liver tissue, but they can rise for many reasons, including temporary strain from illness, medication, alcohol exposure, metabolic factors, or fatty liver disease. GGT and alkaline phosphatase can point toward different patterns, including cholestatic/bile duct patterns or medication and alcohol-related effects depending on the rest of the lab picture.

What matters is not just that a value is flagged high, but how the labs behave over time and what other markers show. Underwriters often look beyond ALT/AST and consider bilirubin, alkaline phosphatase, albumin, INR (or prothrombin time), platelet count, and sometimes imaging or specialist notes. If enzymes are mildly elevated but functional markers look normal and the medical record supports a benign cause, underwriting outcomes can be much more favorable than most people expect.

In practical terms, most liver enzyme cases come down to three underwriting questions: (1) how high are the enzymes, (2) what is the cause or the most likely cause, and (3) what evidence shows stability, improvement, or lack of progressive damage. When those three items are clear, many cases move from “postpone” to “approve,” or from “heavy rating” to “reasonable rating.”

How high is “too high” and why trends matter

Insurers evaluate enzyme elevations based on degree and persistence. Mild elevations that are stable or improving are often treated very differently than persistent elevations that are rising or accompanied by abnormal function markers. Underwriting also becomes more conservative if the elevation is new and there is no follow-up yet, because carriers prefer repeat testing to confirm whether the issue is transient or persistent.

That’s why trend data matters. A single lab result can be misleading. A series of labs over 6–12 months that show stable or improving values can materially change the underwriting posture. When your file shows a consistent monitoring pattern with clear physician assessment, the underwriter has far less reason to assume worst-case scenarios.

Common causes underwriters look for

Underwriting is essentially a risk forecast. Carriers are not only trying to identify a diagnosis—they’re trying to determine whether abnormal labs represent a temporary event, a manageable condition, or a marker of increased mortality risk. The most common causes that show up include the following:

Fatty liver disease (NAFLD / NASH). This is one of the most frequent reasons for elevated ALT/AST. Underwriters often connect it to metabolic health: weight, triglycerides, insulin resistance, and A1C/glucose trends. Mild fatty liver with good documentation and no evidence of advanced fibrosis is often underwritten more reasonably than people expect, especially if follow-up labs show improvement and there is consistent primary care monitoring.

Alcohol-related liver stress. Insurers focus heavily on alcohol history, patterns of use, and any medical notes suggesting heavy intake. Even mild elevations can lead to conservative outcomes if records contain red flags such as physician documentation of heavy use, history of withdrawal, rehab, or alcohol-related legal issues. When the file supports low-risk use and there are no red flags, underwriting can look very different.

Medication or supplement effects. Statins, certain antibiotics, anti-seizure medications, and some supplements can cause transient elevations. The key is documentation—an office note that explains the suspected cause, the monitoring plan, and the follow-up trend can make the underwriter far more comfortable.

Viral hepatitis (past or current). Hepatitis testing can change the case entirely. Resolved infections documented as cleared are evaluated differently than active infection, elevated viral load, or evidence of fibrosis/cirrhosis. If hepatitis is present, carriers often want evidence of treatment, follow-up, and stable functional markers.

Autoimmune or cholestatic disease. Less common but important. If labs suggest an autoimmune or bile-duct pattern, carriers generally want to see specialist involvement, treatment compliance, and stable results over time.

Unexplained elevations. This is where many applicants get stuck. If records show repeated abnormal labs without documented workup or follow-up, carriers frequently assume a higher-risk cause and respond with postponement or heavy ratings. Converting “unknown” into “explained and monitored” is often one of the quickest ways to improve outcomes.

What improves life insurance outcomes with elevated liver enzymes

When we shop liver enzyme cases, we focus on making the underwriter’s decision easy. The strongest outcomes usually follow the same best practices:

1) Show trend data, not a snapshot. Multiple liver panels over time (especially showing stable or improving results) usually underwrite better than a single flagged lab.

2) Document the cause or the most likely cause. Underwriters don’t need an essay. They need the medical record to reflect the suspected cause, what was ruled out, and the clinical assessment of severity. A clear physician note is often more valuable than anything written in the application comments.

3) Separate enzyme elevation from liver function. Elevated enzymes can exist with normal liver function. Normal albumin, normal INR, normal platelets, and reassuring imaging can materially reduce the underwriter’s concern compared to cases where function markers are impaired.

4) Establish a stability window. New elevations without follow-up often lead to postponements. A stable monitoring period—commonly 6–12 months—helps carriers feel comfortable approving coverage.

5) Clarify metabolic context when fatty liver is involved. If NAFLD/NASH is part of the picture, underwriters often tie risk to BMI, blood pressure, A1C/glucose, and lipid control. Improvement here can meaningfully support underwriting outcomes. This is similar to how carriers evaluate other complex medical profiles where multiple markers overlap (see: Life Insurance for Kidney Disease).

6) Match the case to the right carrier appetite. Some carriers are extremely conservative on mild elevations; others are more flexible when documentation is clean. Because we’re independent, we can route your application toward the companies that tend to be most reasonable for your exact pattern.

What insurers typically request

Even when an application starts “simple,” elevated liver enzyme cases often trigger follow-up requests. Knowing what’s common helps reduce delays:

Recent labs. Carriers often want a liver panel and sometimes a complete metabolic panel within the last 6–12 months. If only one abnormal lab is available, many will request repeat labs to confirm stability.

Primary care notes. Underwriters look for physician assessment, alcohol history, weight/metabolic context, and whether a monitoring plan is documented.

Specialist notes (if applicable). If GI/hepatology is involved, those notes can be pivotal—especially when they document no advanced disease, stable findings, or successful treatment.

Imaging. Ultrasound is common. Imaging that supports mild fatty infiltration without advanced changes can help; imaging suggesting fibrosis/cirrhosis shifts underwriting to a more restricted posture.

Hepatitis testing. If viral hepatitis is suspected or documented, carriers often request confirmatory labs and follow-up history.

Alcohol clarification. Elevated enzymes often trigger alcohol-use questions even for light drinkers. Clean documentation and consistent history matter.

When those items are gathered and framed well, the underwriter doesn’t have to speculate. That is the single biggest driver of better outcomes in liver enzyme cases.

How we approach elevated liver enzyme cases

There’s a major difference between applying and hoping versus applying strategically. Our process is built to protect your options and reduce the risk of preventable declines:

We define the underwriting story. Temporary elevation, fatty liver/metabolic, medication effect, viral history, alcohol-related pattern, or another category. The goal is to align your documented story with underwriting expectations.

We focus on the right evidence. Not every medical record helps. The right labs, the right notes, and the right imaging are what matter. Clarity wins.

We match you to the right carrier appetite. Carrier selection is often the difference between “postpone” and “approve,” or between heavy tables and manageable tables.

We prevent avoidable underwriting problems. When labs are unexplained, underwriters default conservative. We work to eliminate “unknown” wherever the record supports it. If timing is a factor, we’ll tell you that upfront so you don’t burn an application attempt unnecessarily.

What coverage is typically available

Many applicants with elevated liver enzymes still qualify for traditional term or permanent coverage. The product fit depends on your age, goals, budget, and underwriting outcome, but the key is getting the underwriting right.

Term life. Often the best value for larger face amounts, especially when enzyme elevations are mild, explained, and stable.

Permanent life. Useful when the goal is lifelong protection, estate planning, or long-term family planning. Carrier appetite can vary more in permanent product lines, which is another reason multi-carrier shopping matters.

Guaranteed issue / graded benefit options. Typically reserved for situations where traditional underwriting is unlikely due to severe or progressive liver disease, multiple compounding conditions, or lack of stability. When traditional coverage is realistically achievable, it’s usually better to pursue that path first.

Example case

A 52-year-old applicant had elevated ALT and AST attributed to fatty liver disease. Prior applications had been postponed due to “abnormal labs” with limited context. With updated labs showing stable trend, a physician note documenting mild fatty liver without advanced changes, and a clearer metabolic health picture, the applicant was approved for traditional coverage with a manageable rating. The difference was not the diagnosis—it was documentation, stability, and carrier selection.

Why Diversified Insurance Brokers

When abnormal labs are part of your file, underwriting can swing widely between carriers. Our role is to reduce uncertainty, prevent unnecessary declines, and present your situation in the most underwriter-friendly way possible—so you can secure meaningful coverage without overpaying.

If you’ve been postponed, declined, or quoted high premiums because of liver labs, there is often a better path by pairing the right documentation with the right carrier. For broader context on underwriting across medical history, you can also review: Life Insurance with Pre-Existing Conditions.